Investigating backup DNA repair mechanisms in certain cancers
Official title: Backup DNA repair in homologous recombination deficient cancers
Funded at Sloan-Kettering Inst Can Research · NIH-11049986 · Data updated 2026-11-12
This study is looking at how some cancers, especially those that struggle with repairing their DNA, fix damage when their usual methods fail, and it focuses on a protein called RAD52 to find new ways to treat these cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | December 1, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $487,393 |
| NIH project number | 1R01CA286111-01A1 |
| Project ID | NIH-11049986 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with homologous recombination deficient cancers, such as those with mutations in the BRCA1 or BRCA2 genes.
✕Less likely to help
Patients with cancers that do not exhibit homologous recombination deficiency may not benefit from this research.
What this research studies
This research focuses on understanding how certain cancers, particularly those deficient in homologous recombination (HRD), repair DNA damage. It examines the role of specific proteins, such as RAD52, in the backup repair processes that occur when the primary repair pathways are compromised. By studying these mechanisms, the research aims to identify new targets for cancer treatment and develop functional assays to better understand DNA repair in these cancer types.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies for patients with HRD cancers, improving their outcomes.
How similar studies have gone: Previous research has shown promising results in targeting backup DNA repair mechanisms in HRD cancers, indicating potential for success in this approach.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Powell, Simon N. — Sloan-Kettering Inst Can Research
- Study coordinator: Powell, Simon N.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.